270 related articles for article (PubMed ID: 10999737)
1. CDKN2A mutation and deletion status in thin and thick primary melanoma.
Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
[TBL] [Abstract][Full Text] [Related]
2. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
3. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
6. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
[TBL] [Abstract][Full Text] [Related]
7. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma.
Sini MC; Manca A; Cossu A; Budroni M; Botti G; Ascierto PA; Cremona F; Muggiano A; D'Atri S; Casula M; Baldinu P; Palomba G; Lissia A; Tanda F; Palmieri G
Br J Dermatol; 2008 Feb; 158(2):243-50. PubMed ID: 18028495
[TBL] [Abstract][Full Text] [Related]
9. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
10. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
[TBL] [Abstract][Full Text] [Related]
11. Hereditary cutaneous melanoma.
Platz A; Ringborg U; Hansson J
Semin Cancer Biol; 2000 Aug; 10(4):319-26. PubMed ID: 10966854
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma.
Ariyanayagam-Baksh SM; Baksh FK; Swalsky PA; Finkelstein SD
Mod Pathol; 2003 Oct; 16(10):992-5. PubMed ID: 14559981
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
14. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
[TBL] [Abstract][Full Text] [Related]
15. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group.
Palmieri G; Cossu A; Ascierto PA; Botti G; Strazzullo M; Lissia A; Colombino M; Casula M; Floris C; Tanda F; Pirastu M; Castello G;
Br J Cancer; 2000 Dec; 83(12):1707-14. PubMed ID: 11104570
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization.
Rákosy Z; Vízkeleti L; Ecsedi S; Bégány A; Emri G; Adány R; Balázs M
Cancer Genet Cytogenet; 2008 Apr; 182(2):116-21. PubMed ID: 18406873
[TBL] [Abstract][Full Text] [Related]
17. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
18. Morphologic diversity in malignant melanoma: the potential use of microdissection and the polymerase chain reaction for diagnosis.
Quezado MM; Abati AD; Albuquerque AV; Wilson J; Merino MJ; Filie AC
Mod Pathol; 1998 Oct; 11(10):1010-5. PubMed ID: 9796732
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
[TBL] [Abstract][Full Text] [Related]
20. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
